SPRC

SPRC

Scisparc Ltd

Net โ€”top 1%Rev โ€”top 1%1Y
Hold

SciSparc Ltd. develops cannabinoid-based pharmaceuticals targeting central nervous system disorders. Its key products include SCI-110 for Tourette syndrome and Alzheimer's, SCI-210 for autism, and CannAmide for pain relief, along with hemp seed oil products.

โš•๏ธ Healthcare NASDAQ Listed 2021 $ USD
$1,000 invested 1 year ago โ†’$143today

Score Overview

1 Year
Scoreโ€”
Net Growthโ€”
Net Trendโ€”
Net Income Consistencyโ€”
Rev Growthโ€”
Rev Trendโ€”
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growthโ€”
Net Trend25%
Net Income Consistency
Rev Growthโ€”
Rev Trend50%
Revenue Consistency

See the full market ranking โ†’

Scisparc Ltd fundamental performance

Across Scisparc Ltd's full reported history, from 2021 to 2025, revenue declined from $ 1M to $ 856K and net income went from -$ 5M to -$ 12M. Revenue increased in 50% of the years measured; net income in 25%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 6.60โ€”
1 Year2025-08-12
$ 46.22-85.72%
All Time2021-08-30
$ 22.11K-99.97%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 4M
2025$ 856K-$ 12M$ 4M
2024$ 1M-$ 6M$ 2M
2023$ 2M-$ 5M$ 5M
2022$ 1M-$ 2M$ 3M
IPO2021$ 1M-$ 5M$ 6M

Explore beyond SPRC

You're looking at Scisparc Ltd. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies